Here, we applied the platform to a cetuximab backbone to generate the final product, Fc-engineered cetuximab (Pin-EGFR)-armed NK cells, and demonstrated its superior in vitro potency against EGFR-expressing cancer cells, focusing on glioblastoma cells. Here, EGFR is linked to cancer.